Asian cardiovascular & thoracic annals · 2013
Preoperative levosimendan in ischemic mitral valve repair.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharma Pranav, Malhotra Amber, Gandhi Sanjay, Garg Pankaj, Bishnoi Arvind, Gandhi Hemang
Аннотация
BACKGROUND: Levosimendan is a new calcium sensitizing drug with vasodilatory and inotropic properties, which is used for the treatment of postoperative low cardiac output syndrome and difficult weaning from cardiopulmonary bypass.
OBJECTIVE: To evaluate the hemodynamic effects of levosimendan during and after coronary artery bypass grafting on cardiopulmonary bypass and mitral valve repair in patients with low left ventricular ejection fractions (<30%).
METHODS: 40 patients were enrolled in this double-blind prospective randomized controlled trial. They received either levosimendan or a placebo preoperatively (n = 20) for 24 h. Clinical parameters were measured before and after administration. Any adverse events during and after drug administration and postoperative complications were evaluated.
RESULTS: Patients treated with levosimendan exhibited a higher cardiac index and mean arterial pressure intraoperative and in the early postoperative period, compared to the control group. Patients treated with levosimendan required less ventilatory support (p < 0.0001) and had shorter intensive care unit (p < 0.0001) and hospital stay (p < 0.0001).
CONCLUSIONS: Preoperative treatment with levosimendan in patients undergoing coronary artery bypass grafting and mitral valve repair resulted in improved hemodynamics and a stable postoperative course.
OBJECTIVE: To evaluate the hemodynamic effects of levosimendan during and after coronary artery bypass grafting on cardiopulmonary bypass and mitral valve repair in patients with low left ventricular ejection fractions (<30%).
METHODS: 40 patients were enrolled in this double-blind prospective randomized controlled trial. They received either levosimendan or a placebo preoperatively (n = 20) for 24 h. Clinical parameters were measured before and after administration. Any adverse events during and after drug administration and postoperative complications were evaluated.
RESULTS: Patients treated with levosimendan exhibited a higher cardiac index and mean arterial pressure intraoperative and in the early postoperative period, compared to the control group. Patients treated with levosimendan required less ventilatory support (p < 0.0001) and had shorter intensive care unit (p < 0.0001) and hospital stay (p < 0.0001).
CONCLUSIONS: Preoperative treatment with levosimendan in patients undergoing coronary artery bypass grafting and mitral valve repair resulted in improved hemodynamics and a stable postoperative course.
Предметные рубрики MeSH
AdultAgedCardiopulmonary BypassCardiotonic AgentsCoronary Artery BypassCoronary Artery DiseaseDouble-Blind MethodFemaleHeart Valve Prosthesis ImplantationHemodynamicsHumansHydrazonesIndiaIntensive Care UnitsLength of StayMaleMiddle AgedMitral Valve AnnuloplastyMitral Valve InsufficiencyPostoperative ComplicationsPreoperative CareProspective StudiesPyridazinesRespiration, ArtificialSimendanTime FactorsTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, Left